Use of lacticaseibacillus paracasei and fermented product thereof for enhancing digestive enzyme activity

Abstract

Disclosed in the present invention is a use of Lacticaseibacillus paracasei and a fermented product thereof for enhancing digestive enzyme activity. The Lacticaseibacillus paracasei is Lacticaseibacillus paracasei PC-01 with the preservation number of CGMCC No. 17537. In the present invention, the Lacticaseibacillus paracasei PC-01 can significantly enhance the activities of lactase, sucrase, and aminopeptidase in a small intestine, and the activity of trypsin in a pancreas; and the fermented product of PC-01 can further significantly enhance the activity of pancreatic lipase in the pancreas, and enhancement of the activities of lactase, aminopeptidase, and pancreatic lipase by the fermented product of PC-01 is significantly superior to that by PC-01.

Description

Application of paracasei in improving digestive enzyme activity

[0001] The present application claims priority to the Chinese patent application No. 202411111880.X, filed on August 14, 2024, with the title of "Application of paracasei in improving digestive enzyme activity", the whole content of which is incorporated herein by reference. TECHNICAL FIELD

[0002] The present application relates to the technical field of digestive enzyme, in particular to the application of paracasei in improving digestive enzyme activity. BACKGROUND

[0003] Digestive enzymes in the digestive tract are a class of proteins that decompose sugars, fats, proteins and other nutrients in food, and play a key role in the digestion and absorption of nutrients in the body. Abnormal digestive enzyme activity is closely related to digestive system diseases. Reduced digestive enzyme activity can lead to incomplete decomposition of food, affecting the digestion and absorption of nutrients, and also easily causing indigestion and other problems.

[0004] The conventional way to improve digestive enzyme activity is to supplement exogenous digestive enzyme preparations, which can effectively improve the activity of digestive enzymes. Common digestive enzyme preparations in clinical practice include multi-enzyme tablets, compound pepsin and pancreatin enteric-coated capsules, etc. These drugs have a certain effect on improving digestive enzyme activity, but they are prone to side effects such as diarrhea, nausea, vomiting and other gastrointestinal symptoms. Some patients also experience allergic symptoms such as skin rash and itching after taking digestive enzymes.

[0005] Currently, some probiotics have been disclosed in the prior art to improve digestive enzyme activity without side effects. However, the types of probiotics that can improve digestive enzyme activity in the intestine are still limited, especially for paracasei, which has not been reported to improve digestive enzyme activity in the intestine. SUMMARY

[0006] Therefore, the purpose of the present application is to solve the problem of limited types of probiotics that can improve digestive enzyme activity in the intestine disclosed in the prior art, and to provide another type of probiotic that can improve digestive enzyme activity in the intestine.

[0007] Specifically, the present application provides the application of a strain of paracasei in improving digestive enzyme activity, wherein the paracasei is paracasei PC-01 with the preservation number of CGMCC No. 17537.

[0008] The original name of the Lactobacillus paracasei PC-01 is Lactobacillus paracasei PC-01. The Lactobacillus paracasei PC-01 is an existing strain, which is purchased and details are not described herein.

[0009] The digestive enzyme is a small intestine digestive enzyme and / or a pancreas digestive enzyme.

[0010] Preferably, the small intestine digestive enzyme includes at least one of lactase, sucrose and aminopeptidase.

[0011] The pancreas digestive enzyme includes trypsin.

[0012] The application of a fermentation product of a Lactobacillus paracasei in improving digestive enzyme activity, wherein the Lactobacillus paracasei is Lactobacillus paracasei PC-01 with the preservation number of CGMCC No.17537.

[0013] The digestive enzyme is a small intestine digestive enzyme and / or a pancreas digestive enzyme.

[0014] The digestive enzyme includes at least one of lactase, sucrose, aminopeptidase, trypsin and pancreatic lipase.

[0015] The fermentation product is a dairy product fermented by the Lactobacillus paracasei PC-01.

[0016] Preferably, the fermentation product is a lactic acid bacteria beverage of the Lactobacillus paracasei PC-01.

[0017] The digestive enzyme is at least one of lactase, aminopeptidase and pancreatic lipase.

[0018] The technical solution of the present application has the following advantages:

[0019] 1. The application provides the application of Lactobacillus paracasei in improving digestive enzyme activity, wherein the Lactobacillus paracasei is Lactobacillus paracasei PC-01 with the preservation number of CGMCC No.17537; the Lactobacillus paracasei PC-01 has the effect of significantly improving the activity of digestive enzymes in the body, especially lactase, sucrose and aminopeptidase in the small intestine, and trypsin in the pancreas; the Lactobacillus paracasei PC-01 of the present application has a significant improvement effect on the activity of the above digestive enzymes.

[0020] 2. The application provides the application of the fermentation product of the Paracaseicillus casei in improving the activity of digestive enzymes, wherein the Paracaseicillus casei is Paracaseicillus casei PC-01 with the preservation number of CGMCC No. 17537; the fermentation product of the Paracaseicillus casei PC-01 has the effect of significantly improving the activity of digestive enzymes in the body, and has the effect of significantly improving the activity of lactase, sucrase and aminopeptidase in the small intestine and the activity of trypsin and pancreatic lipase in the pancreas.

[0021] In addition, the fermentation product of the Paracaseicillus casei PC-01 has a more significant improvement effect on the activity of lactase, aminopeptidase and pancreatic lipase in the body than the Paracaseicillus casei PC-01 alone. BRIEF DESCRIPTION OF DRAWINGS

[0022] In order to more clearly illustrate the specific embodiments of the application or the technical solutions in the prior art, the following will briefly introduce the drawings needed to be used in the specific embodiments or the prior art description. Obviously, the drawings in the following description are some embodiments of the application, and those skilled in the art can also obtain other drawings according to these drawings without creative labor.

[0023] Fig. 1 is a comparison chart of the activity of lactase in the embodiment of the application;

[0024] Fig. 2 is a comparison chart of the activity of sucrase in the embodiment of the application;

[0025] Fig. 3 is a comparison chart of the activity of aminopeptidase in the embodiment of the application;

[0026] Fig. 4 is a comparison chart of the activity of trypsin in the embodiment of the application;

[0027] Fig. 5 is a comparison chart of the activity of pancreatic lipase in the embodiment of the application. DETAILED DESCRIPTION

[0028] The following examples are provided to better further understand the application and are not limited to the best mode of the application, and do not limit the content and protection scope of the application. Any person who obtains any product the same as or similar to the application under the inspiration of the application or by combining the application with other prior art features falls within the protection scope of the application.

[0029] The specific experimental steps or conditions are not indicated in the examples, and can be performed according to the conventional experimental steps or conditions described in the literature in the art. The reagents or instruments used are not indicated by the manufacturer, and are conventional reagent products that can be obtained by purchase.

[0030] EXAMPLE

[0031] A strain of paracasei PC-01 and its fermentation product in improving digestive enzyme activity, the specific verification process is as follows:

[0032] 1) Respectively obtain the bacteria powder of paracasei PC-01 and the lactic acid bacteria beverage of paracasei PC-01; the viable cell number of paracasei PC-01 in the lactic acid bacteria beverage is ≥5×10 8 CFU / mL. The bacteria powder of paracasei PC-01 is configured into PC-01 viable bacteria water with a viable cell number of 1×10 9 CFU / mL using normal saline, and the lactic acid bacteria beverage is concentrated so that its viable cell number also reaches 1×10 9 CFU / mL.

[0033] The bacteria powder of paracasei MN-17 is used as a control group, and the MN-17 viable bacteria water with the same viable cell number as the PC-01 viable bacteria water is configured using normal saline.

[0034] 2) Digestive enzyme activity sample acquisition:

[0035] 6-week-old SD rats are used as experimental model animals, and the body weight of the SD rats ranges from 210-230g. The experimental animals, maintenance feed, and rat bedding are purchased from Sibeifeng (Beijing) Biotechnology Co., Ltd. (SCXK(Jing) 2019-0010). During the experiment, all animals are kept in a 12h / 12h light-dark alternating SPF barrier environment, with a temperature of (22±2)℃, a humidity of (50±10)%, and the model animals are free to eat and drink water. This experiment is approved by the Experimental Animal Welfare and Ethics Committee of Inner Mongolia Agricultural University.

[0036] After adaptive feeding, 44 SD rats are randomly divided into 4 groups, 11 rats in each group; they are respectively experimental group (NC group), paracasei MN-17 group (MN-17 group), paracasei PC-01 group (PC-01 group), and lactic acid bacteria beverage group made of PC-01 (FPC-01 group). During the experiment, they are free to eat and drink water; the NC group is given normal saline by gavage, 2mL / day·1 time; the MN-17 group is given MN-17 viable bacteria water by gavage, 2mL / day·1 time; the PC-01 group is given PC-01 viable bacteria water by gavage, 2mL / day·1 time; the FPC-01 group is given lactic acid bacteria beverage of paracasei PC-01 by gavage, 2mL / day·1 time. After 4 weeks (28d) of gavage, the SD rats are sacrificed and the stomach contents, small intestine contents, pancreas, and other samples are collected.

[0037] 3) Digestive enzyme activity detection in samples:

[0038] The lactase activity in the small intestine contents was detected by using a conventional lactase activity detection method, and the detection results are shown in Figure 1. The lactase activities of the NC group, the MN-17 group, the PC-01 group and the FPC-01 group were 75.0±7.2 U / g, 76.2±8.1 U / g, 88.0±11.9 U / g and 103.0±13.2 U / g, respectively. The MN-17 group had no significant difference with the NC group, the PC-01 group (P=0.002) and the FPC-01 group (P<0.001) had significant differences with the NC group, and the FPC-01 group was significantly higher than the PC-01 group (P=0.002).

[0039] The sucrase activity in the small intestine contents was detected by using a conventional sucrase activity detection method, and the detection results are shown in Figure 2. The sucrase activities of the NC group, the MN-17 group, the PC-01 group and the FPC-01 group were 181.1±19.2 U / g, 185.2±20.3 U / g, 198.6±24.4 U / g and 202.7±31.8 U / g, respectively. The MN-17 group had no significant difference with the NC group, the PC-01 group (P=0.03) and the FPC-01 group (P=0.03) had significant differences with the NC group, and the FPC-01 group had no significant difference with the PC-01 group.

[0040] The aminopeptidase activity in the small intestine contents was detected by using a conventional aminopeptidase activity detection method, and the detection results are shown in Figure 3. The aminopeptidase activities of the NC group, the MN-17 group, the PC-01 group and the FPC-01 group were 123.0±7.9 U / g, 127.3±9.2 U / g, 143.2±13.2 U / g and 156.4±12.6 U / g, respectively. The MN-17 group had no significant difference with the NC group, the PC-01 group (P<0.001) and the FPC-01 group (P<0.001) had significant differences with the NC group, and the FPC-01 group was significantly higher than the PC-01 group (P=0.008).

[0041] The trypsin activity in the pancreas was detected by using a conventional trypsin activity detection method, and the detection results are shown in Figure 4. The trypsin activities of the NC group, the MN-17 group, the PC-01 group and the FPC-01 group were 0.43±0.06 U / g, 0.44±0.04 U / g, 0.50±0.03 U / g and 0.47±0.05 U / g, respectively. The MN-17 group had no significant difference with the NC group, the PC-01 group (P=0.003) and the FPC-01 group (P<0.001) had significant differences with the NC group, and the FPC-01 group had no significant difference with the PC-01 group.

[0042] The pancreatic lipase activity in the pancreas was detected by using the conventional pancreatic lipase activity detection method, and the detection results are shown in Figure 5. The pancreatic lipase activities of the NC group, the MN-17 group, the PC-01 group, and the FPC-01 group were 0.225±0.019 U / g, 0.226±0.018 U / g, 0.228±0.016 U / g, and 0.238±0.014 U / g, respectively. The MN-17 group had no significant difference with the NC group, the PC-01 group had no significant difference with the NC group, and the FPC-01 group was significantly higher than the NC group (P=0.04) and the PC-01 group (P=0.06).

[0043] In Figures 1-5 of the above detection results, different letters represent significant differences between groups, and the same letter represents no significant difference between groups.

[0044] 4) Digestive enzyme activity analysis in samples:

[0045] From the results of Figures 1-5 above, it can be seen that PC-01 and the lactic acid bacteria beverage prepared from PC-01 can significantly improve the activities of lactase, sucrase, and aminopeptidase in the small intestine, and can also significantly improve the activity of trypsin in the pancreas. The lactic acid bacteria beverage prepared from PC-01 can also significantly improve the activity of pancreatic lipase in the pancreas, and the improvement of the lactic acid bacteria beverage prepared from PC-01 in the activities of lactase, aminopeptidase, and pancreatic lipase is significantly better than that of PC-01.

[0046] Obviously, the above embodiments are only examples for the purpose of clarity, and are not limitations on the embodiments. Based on the above description, other different forms of changes or variations can be made by those of ordinary skill in the art. It is not necessary or possible to exhaust all embodiments. The obvious changes or variations derived therefrom are still within the protection scope of the present application.

Claims

1. Use of a Paracaseiclovarcasei strain for increasing the activity of digestive enzymes, characterized in that, The Paracaseicilus casei is Paracaseicilus casei PC-01 with the preservation number of CGMCC No. 17537.

2. Use according to claim 1, characterized in that, The digestive enzyme is a small intestine digestive enzyme and / or a pancreas digestive enzyme.

3. Use according to claim 2, characterized in that, The small intestine digestive enzyme includes at least one of lactase, sucrose and aminopeptidase.

4. Use according to claim 2, characterized in that, The pancreas digestive enzyme includes trypsin.

5. Use of a fermentation product of Paracaseiclovarcasei for increasing the activity of digestive enzymes, characterized in that, The Paracaseicilus casei is Paracaseicilus casei PC-01 with the preservation number of CGMCC No. 17537.

6. Use according to claim 5, characterized in that, The digestive enzyme is a small intestine digestive enzyme and / or a pancreas digestive enzyme.

7. Use according to claim 6, characterized in that, The digestive enzyme includes at least one of lactase, sucrose, aminopeptidase, trypsin and pancreatic lipase.

8. Use according to any one of claims 5 to 7, characterized in that, The fermentation product is a dairy product fermented by Paracaseicilus casei PC-01.

9. Use according to claim 8, characterized in that, The fermentation product is a lactic acid bacteria beverage of Paracaseicilus casei PC-01.

10. Use according to claim 9, characterized in that, The digestive enzyme is at least one of lactase, aminopeptidase and pancreatic lipase.

Images